10.78
Tyra Biosciences Inc Aktie (TYRA) Neueste Nachrichten
What analysts say about Tyra Biosciences Inc. stockHigh-octane gains - Autocar Professional
Tyra Biosciences (NASDAQ:TYRA) Trading Down 3% – Here’s Why - Defense World
Tyra Biosciences Inc. Stock Analysis and ForecastRecord-setting profit potential - jammulinksnews.com
What drives Tyra Biosciences Inc. stock priceExponential return rates - jammulinksnews.com
Is Tyra Biosciences Inc. a good long term investmentRemarkable growth - jammulinksnews.com
Why Tyra Biosciences Inc. stock attracts strong analyst attentionHigh Yield Opportunities - Newser
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series - Kilgore News Herald
June Brings on Some Huge Insider Buying - AOL.com
What analysts say about HOOK stockPhenomenal capital appreciation - jammulinksnews.com
Trading (TYRA) With Integrated Risk Controls - news.stocktradersdaily.com
What drives Diana Shipping Inc. stock priceSuperior profit margins - Jammu Links News
What drives Third Harmonic Bio Inc. stock priceOutstanding risk-reward balance - jammulinksnews.com
Tyra Biosciences Rises On Precision Medicine Hopes And Analyst Support - Finimize
What makes Tyra Biosciences Inc. stock price move sharplySmart Return Focused Trading - Newser
How Tyra Biosciences Inc. stock performs during market volatilityInsider Strategy Insight - Newser
Tyra Biosciences Insider Lowered Holding By 58% During Last Year - simplywall.st
Advanced Urothelial Carcinoma Clinical Trials 2025: EMA, PDMA, - openPR.com
Oppenheimer Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025 - Eastern Progress
Tyra Biosciences' TYRA-300 Emerges as Dual-Threat Therapy, Poised to Drive Clinical and Market Momentum - AInvest
New TYRA-300 Preclinical Data Reveals Promising Results for Rare Bone Growth Disorder Treatment - Stock Titan
Where are the Opportunities in (TYRA) - news.stocktradersdaily.com
Tyra Biosciences’ (TYRA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC - Targeted Oncology
Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - Longview News-Journal
Tyra Biosciences, Inc.(NasdaqGS: TYRA) added to Russell 2000 Value Index - MarketScreener
Tyra Bioscience Launches Phase 2 Study for TYRA-300 - TipRanks
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):